This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AMN Healthcare Invests In Leading Telepharmacy Company PipelineRx

Stocks in this article: AHS





SAN DIEGO, March 17, 2014 /PRNewswire/ --  AMN Healthcare Services, Inc. (NYSE: AHS), the innovator in healthcare workforce solutions and largest provider of staffing services in the nation, announced today it has made a strategic investment in PipelineRx, a leading clinical telepharmacy company.

Logo - http://photos.prnewswire.com/prnh/20100111/LA35461LOGO 

"Our investment in PipelineRx is a testament to our commitment to investing in innovative solutions to help clients manage their workforce and patient care commitments in the wake of unprecedented changes in the healthcare environment. PipelineRx's telepharmacy offerings address significant healthcare access challenges in a cost-effective manner and increase the quality and safety of care delivered," said Susan Salka, AMN's President and CEO. "We look forward to working closely with PipelineRx to further its mission and identify ways that AMN can leverage our pharmacy staffing division and client relationships to create synergies for both companies."

PipelineRx offers telepharmacy services and technology solutions designed to help hospitals provide cost-efficient pharmacist coverage 24 hours a day with improved patient care. PipelineRx's Clinical Process Outsourcing (CPO) solution uses a private network of quality clinical telepharmacists to replicate and extend the same cognitive clinical roles and responsibilities of a hospital's onsite clinical pharmacists.

PipelineRx also offers its technology as a Software as a Service (SaaS) solutions platform to clients that prefer to use the PipelineRx workflow technology with the hospital's internal pharmacists. This proprietary technology platform optimizes pharmacy operations and labor, streamlines disparate processes, improves financial performance, and helps facilitate government mandates related to verification of electronic physician orders.

"We are pleased to be partnering with AMN Healthcare as we continue to expand the market for our telepharmacy solutions and grow our business in 2014 and beyond. AMN's investment validates our unique approach to improving efficiency in our healthcare system and to drive measurable and enhanced quality of care for patients through the use of cutting-edge technology," said Brian J. Roberts, President of PipelineRx. "With AMN's workforce solutions expertise and staffing services leadership, we look forward to what we can accomplish together to help hospitals achieve financial and patient care goals."

AMN has committed to a $5.0 million investment in staged payments. In conjunction with the investment, AMN also announced that Denise Jackson, General Counsel and Senior Vice President, has joined the PipelineRx Board of Directors. Ms. Jackson will serve as an advisor to the company, drawing upon her experience building AMN's corporate capabilities and nearly 15 years' experience in the healthcare staffing and workforce solutions industry. 



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs